|
This Week in Cell
GenomeWeb A Memorial Sloan Kettering-led team tracks tumor genomic changes in individuals with advanced melanoma receiving the anti-PD-1 immune checkpoint treatment nivolumab. Using a combination of exome sequencing, transcriptome sequencing, and T-cell … |
Source: Genome Sequencing